Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2021 Jan 14;41(3):1167–1178. doi: 10.1161/ATVBAHA.120.315369

Figure 4: Low dose ABT-737 normalizes platelets in diabetic Apoe−/− mice.

Figure 4:

A) Experimental overview: Apoe−/− mice were made diabetic (STZ) or left as control and fed a standard laboratory diet for 12 weeks. After 6 weeks, a group of the diabetic mice were treated with ABT-737 (30mg/kg/tri-weekly i.p.) for additional 6 weeks. B) Blood glucose (n=7/group) and C) plasma cholesterol levels were measured at the end of the study (n=7, 7, 5/group). Circulating D) platelets, E) percentage and F) number of reticulated platelets (n=7/group), and G) leukocytes were measured by flow cytometry (n=5-6/group). H) BM Haematopoietic stem and progenitor cells were quantified by flow cytometry (n=6-7/group). Data are presented mean ± SEM and analyzed using a one-way ANOVA followed by a Dunnett’s multiple comparisons test, biological replicates n=5-7/group; *p<0.05, **p<0.01, ****p<0.0001 c.f. control, or as indicated.